Acute pancreatitis primary prevention
|
Acute pancreatitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acute pancreatitis primary prevention On the Web |
|
American Roentgen Ray Society Images of Acute pancreatitis primary prevention |
|
Risk calculators and risk factors for Acute pancreatitis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monish Thuvooru Muthu Kalyanaraman, M.B.B.S[2]
Primary Prevention
Primary prevention of acute pancreatitis is possible primarily for post-ERCP pancreatitis. Forsmark et al. (NEJM 2016) noted that "primary prevention of pancreatitis is possible only in the case of pancreatitis caused by ERCP." Beyond ERCP-related strategies, prevention focuses on management of modifiable risk factors (alcohol, smoking, hypertriglyceridemia) and appropriate patient selection for ERCP.[1][2][3]
Prevention of Post-ERCP Pancreatitis
Post-ERCP pancreatitis (PEP) prevention is the most evidence-rich area of primary prevention and involves three complementary strategies.[2][4]
Rectal NSAIDs
Rectal indomethacin or diclofenac (100 mg) should be administered to prevent PEP. The ACG 2024 formal recommendation targets patients at high risk for PEP (strong recommendation, moderate quality of evidence), while the ACG 2024 summary text and the ASGE/ACG 2026 quality indicators extend this to all patients with an intact papilla undergoing ERCP unless contraindicated (performance target ≥90%).[2][5]
Meta-analyses demonstrate an approximately 50% relative risk reduction.[5][4] A large-scale RCT of >2,000 average-risk patients confirmed a 54% relative risk reduction, establishing efficacy in unselected patients — not just high-risk cases.[5][4] Pre-procedural administration is preferred based on RCT evidence showing superiority over post-procedural timing.[4] Contraindications include NSAID allergy and significant renal dysfunction.[5]
A 2026 multicenter RCT (n=2,562) demonstrated noninferiority of 50 mg versus 100 mg rectal indomethacin for PEP prevention, though 100 mg may be preferable in patients with a history of pancreatitis.[6]
Prophylactic Pancreatic Duct Stenting
In high-risk patients, the combination of rectal indomethacin plus a prophylactic pancreatic duct stent is superior to indomethacin alone. The NIH-sponsored Stent versus Indomethacin trial (Elmunzer et al., Lancet 2024; 20 centers, n=1,950) found PEP rates of 14.9% with indomethacin alone versus 11.3% with indomethacin plus stent (risk difference 3.6%; p=0.011 for superiority), with numerically fewer cases of severe pancreatitis and pancreatitis-related death.[7][2][4]
However, stent placement is technically complex (4–10% failure rate), and failed placement is itself an independent risk factor for PEP (up to 35% incidence).[8][4] A case-by-case approach is recommended, weighing the patient's PEP risk against the anticipated difficulty of stent placement.[2][4]
Periprocedural Hydration with Lactated Ringer Solution
Multiple RCTs have shown that aggressive periprocedural hydration (3 mL/kg/h during ERCP, 20 mL/kg bolus post-procedure, then 3 mL/kg/h for 8 hours) reduces PEP incidence.[2][4] The ACG 2024 guidelines recommend periprocedural hydration for all patients undergoing ERCP.[2]
However, the incremental benefit when rectal NSAIDs are already given is uncertain — one large rigorous trial showed no additional benefit — and the prolonged infusion is not feasible in outpatient settings where most patients are discharged within 2 hours.[4] European guidelines (ESGE) restrict this recommendation to patients with contraindications to NSAIDs.[4][9]
Additional Pharmacologic Strategies
Sublingual nitrates may provide additional benefit when combined with rectal NSAIDs. A multicenter RCT (Tomoda et al., Gastroenterology 2019) demonstrated that diclofenac plus sublingual isosorbide dinitrate reduced PEP by 40.8% compared with diclofenac alone (NNT=26).[10] A 2024 meta-analysis of 10 RCTs (3,240 patients) confirmed glyceryl trinitrate significantly reduces PEP overall.[11] This combination is not yet incorporated into major US guidelines but is supported by ESGE and Japanese guidelines.[10]
Guidewire cannulation rather than contrast-guided cannulation reduces PEP risk and is standard practice.[2]
Appropriate Patient Selection for ERCP
Appropriate patient selection for ERCP is a fundamental prevention strategy. Diagnostic ERCP should be avoided when noninvasive alternatives (MRCP, EUS) are equally accurate and carry no pancreatitis risk.[2] PEP risk is substantially higher in patients with a normal-caliber CBD and normal bilirubin (OR 3.4) compared with jaundiced patients with a dilated duct (OR 0.2).[2]
| Strategy | Recommendation | Key Evidence |
|---|---|---|
| Rectal NSAIDs (indomethacin/diclofenac 100 mg) | High-risk (ACG formal rec); all intact papilla (summary + quality indicators) | ~50% RRR; large RCT in average-risk patients |
| Prophylactic PD stent + NSAID | High-risk patients (case-by-case) | Elmunzer 2024: 14.9% vs 11.3% (RD 3.6%) |
| Periprocedural LR hydration | All patients (ACG); limited incremental benefit with NSAIDs | Multiple RCTs; feasibility issues in outpatient setting |
| Sublingual nitrates + NSAID | Emerging; not yet US guideline-endorsed | Tomoda RCT (NNT=26); 2024 meta-analysis |
| Guidewire cannulation | Standard practice | Reduces PEP vs contrast-guided technique |
Modifiable Risk Factor Management
Modifiable risk factor management addresses the two leading causes of acute pancreatitis — gallstones and alcohol — as well as hypertriglyceridemia.[2][3][12]
- Alcohol cessation — Heavy alcohol consumption (>50 g/day for >5 years) is the second most common cause (~30% of cases). Only ~2–5% of heavy drinkers develop pancreatitis, suggesting cofactors. A dose-dependent relationship exists, with pattern differences between sexes (J-shaped in women, monotonic in men). Structured brief interventions to encourage abstinence are effective but underutilized.[2][3][13][1]
- Smoking cessation — Smoking is an independent risk factor for pancreatitis and accelerates progression of alcohol-induced disease. Cessation counseling should be provided to all patients with pancreatitis risk factors.[14][13][3]
- Triglyceride control — Hypertriglyceridemia (TG ≥1,000 mg/dL) accounts for 2–7% of acute pancreatitis and carries higher severity. Lowering TG by ≥40% is associated with reduced pancreatitis risk based on analyses of RCTs with apoC-III-targeting drugs. Fibrates (fenofibrate) have the greatest TG-lowering efficacy and may be combined with omega-3 fatty acids, statins, or niacin for refractory cases. Dietary modification and weight reduction are foundational.[3][15][12]
- Medication review — Drug-induced pancreatitis accounts for <5% of cases. Strongest evidence exists for didanosine, asparaginase, azathioprine, valproic acid, 6-mercaptopurine, and mesalamine. Identifying and withdrawing the offending agent may prevent recurrence, but misattribution is common — alternative causes should be excluded first.[3][1]
Clinically Actionable Recommendations
- Administer rectal indomethacin or diclofenac 100 mg according to ACG 2024 formal high-risk recommendation and/or the broader ASGE/ACG 2026 quality indicator (target ≥90% for intact papilla).[2][5]
- Consider combination rectal NSAID + prophylactic PD stent in high-risk patients on a case-by-case basis (Elmunzer 2024: 14.9% vs 11.3%).[7][2]
- Avoid diagnostic ERCP when MRCP or EUS can provide equivalent information.[2]
- Counsel all at-risk patients on alcohol cessation, smoking cessation, and triglyceride control.[2][3]
- Review and discontinue implicated medications after excluding alternative etiologies.[3]
References
- ↑ 1.0 1.1 1.2 Forsmark CE, Vege SS, Wilcox CM (2016). "Acute Pancreatitis". N Engl J Med. 375 (20): 1972–1981. doi:10.1056/NEJMra1505202.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 Tenner S, Vege SS, Sheth SG; et al. (2024). "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis". Am J Gastroenterol. 119 (3): 419–437. doi:10.14309/ajg.0000000000002645.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Trikudanathan G, Yazici C, Evans Phillips A, Forsmark CE (2024). "Diagnosis and Management of Acute Pancreatitis". Gastroenterology. 167 (4): 673–688. doi:10.1053/j.gastro.2024.02.052.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 Barakat M, Saumoy M, Forbes N, Elmunzer BJ (2025). "Complications of Endoscopic Retrograde Cholangiopancreatography". Gastroenterology. 169 (2): 230–243.e8. doi:10.1053/j.gastro.2025.03.009.
- ↑ 5.0 5.1 5.2 5.3 5.4 Anderson MA, Cote GA, Keswani RN; et al. (2026). "Quality Indicators for ERCP". Am J Gastroenterol. 121 (1): 80–95. doi:10.14309/ajg.0000000000003825.
- ↑ Qi ZP, Wan R, Wan XJ; et al. (2026). "Low-Dose Rectal Indomethacin to Prevent Post-Ercp Pancreatitis: Results of a Large Chinese Multicenter Randomized Noninferiority Trial". Endoscopy. 58 (7): 689–698. doi:10.1055/a-2840-3508.
- ↑ 7.0 7.1 Elmunzer BJ, Foster LD, Serrano J; et al. (2024). "Indomethacin With or Without Prophylactic Pancreatic Stent Placement to Prevent Pancreatitis After ERCP: A Randomised Non-Inferiority Trial". Lancet. 403 (10425): 450–458. doi:10.1016/S0140-6736(23)02356-5.
- ↑ Chandrasekhara V, Khashab MA, Muthusamy VR; et al. (2017). "Adverse Events Associated With ERCP". Gastrointest Endosc. 85 (1): 32–47. doi:10.1016/j.gie.2016.06.051.
- ↑ Akshintala VS, Sperna Weiland CJ, Bhullar FA; et al. (2021). "Non-Steroidal Anti-Inflammatory Drugs, Intravenous Fluids, Pancreatic Stents, or Their Combinations for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Systematic Review and Network Meta-Analysis". Lancet Gastroenterol Hepatol. 6 (9): 733–742. doi:10.1016/S2468-1253(21)00170-9.
- ↑ 10.0 10.1 Tomoda T, Kato H, Ueki T; et al. (2019). "Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography". Gastroenterology. 156 (6): 1753–1760.e1. doi:10.1053/j.gastro.2019.01.267.
- ↑ Zhang X, Zhang JM, Wei W, Lin H (2024). "Nitroglycerin Combined With NSAIDs for Prevention of Post-Ercp Pancreatitis: A Meta-Analysis of Prospective, Randomized, Controlled Trials". Medicine (Baltimore). 103 (27): e38764. doi:10.1097/MD.0000000000038764.
- ↑ 12.0 12.1 Mederos MA, Reber HA, Girgis MD (2021). "Acute Pancreatitis: A Review". JAMA. 325 (4): 382–390. doi:10.1001/jama.2020.20317.
- ↑ 13.0 13.1 Wang F, Görgülü K, Algül H, Hu LH (2026). "The Role of Alcohol in Pancreatic Diseases: A Comprehensive Perspective". Gastroenterology. 170 (2): 268–286. doi:10.1053/j.gastro.2025.08.025.
- ↑ Shelton C, LaRusch J, Whitcomb DC (2020). "Pancreatitis Overview". GeneReviews®.
- ↑ Subramanian S, Soran H, Sikora Kessler A; et al. (2025). "Prevention and Treatment of Hypertriglyceridemia-Mediated Acute Pancreatitis: A Narrative Review". Eur J Intern Med: 106648. doi:10.1016/j.ejim.2025.106648.